Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30023683 | 0.83 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL3892672 | 0.82 | DGAT1 (0.38) | DGAT1 | |
| Hydrochloric Acid SCHEMBL1357352 | 0.80 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL3428450 | 0.78 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL27850761 | 0.78 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL24242159 | 0.77 | DGAT1 (0.48) | DGAT1CA12CA2CA14 | |
| SCHEMBL14485421 | 0.77 | DGAT1 (0.48) | DGAT1CA12CA14 | |
| SCHEMBL14485423 | 0.77 | DGAT1 (0.48) | DGAT1CA12CA14 | |
| SCHEMBL3383788 | 0.77 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL16326806 | 0.77 | DGAT1 (0.48) | DGAT1CA12CA2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-9896439-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-9849136-B2 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170182057-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-9617254-B2 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170081320-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-7786110-B2 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100152203-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-06-17 | — | — | US | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
| US-7595405-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20080132494-A1 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | P2RX2, P2RX3, TPX2 | DGAT1 3988/4885CA12 3974/4885CA2 825/4885 |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | DGAT1 4329/4885CA12 4496/4885CA2 1115/4885 |
| US-20170182057-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | DGAT1 4745/4885CA12 3557/4885CA2 470/4885 |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX1 | DGAT1 4837/4885CA12 4803/4885CA2 1480/4885 |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | P2RX2, P2RX3, TPX2 | DGAT1 3940/4885CA12 3997/4885CA2 845/4885 |
| US-20170081320-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | DGAT1 4343/4885CA12 4823/4885CA2 1605/4885 |
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | DGAT1 4745/4885CA12 4564/4885CA2 1157/4885 |
| US-20100152203-A1 | THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | DGAT1 4343/4885CA12 4823/4885CA2 1605/4885 |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | DGAT1 4413/4885CA12 4563/4885CA2 931/4885 |
| US-20080132494-A1 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX1 | DGAT1 4743/4885CA12 3513/4885CA2 453/4885 |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | P2RX3, P2RX2, P2RX5 | DGAT1 4195/4885CA12 4463/4885CA2 1000/4885 |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX5 | DGAT1 4195/4885CA12 4463/4885CA2 1000/4885 |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | DGAT1 4745/4885CA12 4564/4885CA2 1157/4885 |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | DGAT1 4847/4885CA12 4727/4885CA2 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.